An appraisal of the histopathological assessment of liver fibrosis

Gut

Volumn 55, Issue 4, 2006, Pages 569-578

  Standish, R A ^a   Cholongitas, E ^a   Dhillon, A ^a   Burroughs, A K ^a   Dhillon, A P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN;

CHRONIC DISEASE; CHRONIC LIVER DISEASE; DIAGNOSTIC ACCURACY; GENETIC VARIABILITY; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; METHODOLOGY; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; VIRUS HEPATITIS;

BIOLOGICAL MARKERS; BIOPSY; CHRONIC DISEASE; COLLAGEN; DISEASE PROGRESSION; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER; LIVER CIRRHOSIS; OBSERVER VARIATION;

EID: 33645124543     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.084475     Document Type: Review

References (67)

1. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-8.
2. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998;43:2573-6.
3. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-5.
4. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
5. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
6. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
7. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
8. Westin J, Lagging LM, Wejstal R, et al. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999;19:183-7.
9. Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996;25:649-54.
10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
11. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41:257-64.
12. Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis. 2002;6:335-47, v-vi).
13. National Institute for Clinical Excellence. Summary of guidance issued to the NHS in England and Wales. Compilation 2003;7:187-8.
14. Wright M, Forton D, Main J, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005;12:58-66.
15. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
16. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
17. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
18. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
19. Siddique I, El Naga HA, Madda JP, et al. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003;38:427-32.
20. Persico M, Palmentieri B, Vecchione R, et al. Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. Am J Gastroenterol 2002;97:491-2.
21. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
22. Farrell RJ, Smiddy PF, Pilkington RM, et al. Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol 1999;30:580-7.
23. Hopper KD, Abendroth CS, Sturtz KW, et al. Blinded comparison of biopsy needles and automated devices in vitro: 1. Biopsy of diffuse hepatic disease. AJR Am J Roentgenol 1993;161:1293-7.
24. Rocken C, Meier H, Klauck S, et al. Large-needle biopsy versus thin-needle biopsy in diagnostic pathology of liver diseases. Liver 2001;21:391-7.
25. Chau TN, Tong SW, Li TM, et al. Transjugular liver biopsy with an automated trucut-type needle: comparative study with percutaneous liver biopsy. Eur J Gastroenterol Hepatol 2002;14:19-24.
26. Chevallier P, Ruitort F, Denys A, et al. Influence of operator experience on performance of ultrasound-guided percutaneous liver biopsy. Eur Radiol 2004;14:2086-91.
27. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology 1998;28:323-31.
28. Gurakar A, Balkan M, Fagiuoli S, et al. Experience with percutaneous liver biopsies using two different needles: a 14 G Tru cut needle or a 15 G needle gun. Hepatology 1993;18(suppl 1):P911.
29. Spirchez Z, Fayad E, Albu S, et al. Comparison of two needles, the surecut (18G) versus the biopty gun (18G) in percutaneous liver biopsy. Hepatology 1999;30(suppl 1):P1279.
30. Regan J, Mihalov M, Limjoko A, et al. Transjugular liver biopsy: evaluation and comparison with percutaneous biopsy. Hepatology 1997;26(suppl 1):P281.
31. Judmaier G, Prior C, Klimpfinger M, et al. Is percutaneous liver biopsy using the Trucut (Travenol) needle superior to Menghini puncture? Z Gastroenterol 1989;27:657-61.
32. Tobkes AI, Nord HJ. Liver biopsy: review of methodology and complications. Dig Dis 1995;13:267-74.
33. DiMichele DM, Mirani G, Wilfredo CP, et al. Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. Haemophilia 2003;9:613-18.
34. De Hoyos A, Loredo ML, Martinez-Rios MA, et al. Transjugular liver biopsy in 52 patients with an automated Trucut-type needle. Dig Dis Sci 1999;44:177-80.
35. Cholongitas E, Quaglia A, Samonakis D, et al. Transjugular liver biopsy: is it effective for accurate histological interpretation? Gut 2005;54:P26.
36. Guido M, Rugge M. Liver fibrosis: natural history may be affected by the biopsy sample. Gut 2004;53:1878.
37. Thomson W (Baron Kelvin) Popular lectures and addresses, vol 1. Constitution of matter. London: Macmillan and Co, 1889.
38. Lee HS, Shun CT, Chiou LL, et al. Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: Emphasis on sampling variability. J Gastroenterol Hepatol 2005;20:1109-14.
39. Rojkind M, Ponce-Noyola P. The extracellular matrix of the liver. Coll Relat Res 1982;2:151-75.
40. Feldman G. Critical analysis of the methods used to morphologically quantify hepatic fibrosis. J Hepatol 1995;22(suppl 2):49-52.
41. James J, Bosch KS, Aronson DC, et al. Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver 1990;10:1-5.
42. Puchtler H, Meloan SN, Waldrop FS. Are picro-dye reactions for collagens quantitative? Chemical and histochemical considerations. Histochemistry 1988;88:243-56.
43. Biogini G, Ballardini G. Liver fibrosis and extracellular matrix. J Hepatol 1989;8:115-24.
44. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257-65.
45. O'Brien MJ, Keating NM, Elderiny S, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 2000;114:712-18.
46. Kage M, Shimamatu K, Nakashima E, et al. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 1997;25:1028-31.
47. Duchatelle V, Marcellin P, Giostra E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 1998;29:20-8.
48. Pilette C, Rousselet MC, Bedossa P, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998;28:439-46.
49. Masseroli M, Caballero T, O'Valle F, et al. Automatic quantification of liver fibrosis: design and validation of a new image analysis method: comparison with semi-quantitative indexes of fibrosis. J Hepatol 2000;32:453-64.
50. Manabe N, Chevallier M, Chossegros P, et al. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993;18:1344-9.
51. Lazzarini A, Levine R, Ploutz-Snyder R, et al. Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver Int 2005;25:1142-9.
52. Hui AY, Liew CT, Go MY, et al. Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. liver Int 2004;24:611-18.
53. Wright M, Thursz M, Pullen R, et al. Quantitative versus morphological assessment of liver fibrosis: semi-quantitative scores are more robust than digital image fibrosis area estimation. Liver Int 2003;23:28-34.
54. Papatheodoridis GV, Patch D, Watkinson A, et al. Transjugular liver biopsy in the 1990s: a 2-year audit. Aliment Pharmacol Ther 1999;13:603-8.
55. Corr P, Beningfield SJ, Davey N. Transjugular liver biopsy: a review of 200 biopsies. Clin Radiol 1992;45:238-9.
56. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.
57. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
58. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
59. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
60. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, MCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8.
61. Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology 2004;127:1847-9.
62. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
63. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
64. Hui AY, Chan HL, Wong VW, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005;100:616-23.
65. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
66. Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am J Gastroenterol 2005;100:1981-3.
67. Claassen J. The gold standard: not a golden standard. BMJ 2005;330:1121.